Document:

EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SHARES THAT MAY BE PURCHASED HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS OF ANY
STATE. THIS WARRANT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO DISTRIBUTION, AND THIS WARRANT AND THE SHARES THAT MAY BE PURCHASED HEREUNDER MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933, AND REGISTRATION OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL THAT THE PROPOSED TRANSACTION DOES NOT VIOLATE THE SECURITIES ACT OF 1933, AND APPLICABLE STATE SECURITIES
LAWS. 
 LIVONGO HEALTH, INC. 

WARRANT 
  

			
	Date of Issuance: March 1, 2015	 	Certificate No. 1

 THIS IS TO CERTIFY that CERNER CAPITAL, INC., a Delaware corporation (the “Holder”), for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, is entitled to purchase from LIVONGO HEALTH, INC., a Delaware corporation (the “Company”), at the price of $1.14 per share (the
“Exercise Price”), up to 3,473,618 shares of Common Stock, with a par value of $0.001 per share, of the Company (“Common Stock”) on the terms and subject to the conditions set forth herein. The number of shares of
Common Stock purchasable hereunder and the Exercise Price set forth above shall be adjusted under certain conditions specified in Section 5 of this Warrant. Capitalized terms used but not defined herein shall have the
meanings ascribed to such terms in Section 8 hereof. 
 This Warrant is being issued pursuant to that certain Value Added Reseller
Agreement effective as of the date hereof (the “Agreement”) between the Company and Cerner Corporation (an Affiliate of the Holder). 

SECTION 1. 
 EXERCISE

 (a) Right to Exercise. This Warrant shall be exercisable during the ten-year period
commencing on the date hereof and ending on February 28, 2025 (the “Option Period”) as to that number of Warrant Shares, and at such times, as are determined in accordance with Exhibit A attached hereto and made a part
hereof. The Holder, in accordance with the terms hereof, may exercise this Warrant by delivering (i) the Notice of Exercise, in the form attached hereto as Exhibit B and made a part hereof (the “Notice of
Exercise”), duly executed, and (ii) the Exercise Price per share for each share of Common Stock purchased, as specified in the Notice of Exercise. The aggregate Exercise Price (the “Aggregate Exercise Price”) to be
paid for the shares of Common Stock to be purchased (the “Exercise Amount”) shall be equal to the product of (i) the Exercise Amount multiplied by (ii) the Exercise Price. 

(b) Payment of the Aggregate Exercise Price. Payment of the Aggregate Exercise Price shall be made to the Company in cash or other
immediately available funds. 
 (c) Stockholders Agreements. In addition to the Notice of Exercise, upon the first exercise of this
Warrant, the Holder shall execute and deliver counterpart signature pages to the Stockholders Agreements. Upon the receipt of the duly executed counterpart signature pages to the Stockholders Agreement, the Company shall take all action reasonably
necessary to add the Holder as a party to the Stockholders Agreements. 

 (d) Issuance of Shares of Common Stock. Upon receipt by the Company of the Notice of
Exercise, payment of the Aggregate Exercise Price and the executed counterpart signatures to the Stockholders Agreements, the Holder shall be deemed to be the holder of record of the shares of Common Stock issuable upon such exercise,
notwithstanding that certificates representing such shares of Common Stock may not then be actually delivered. Within five (5) business days after such delivery of the Notice of Exercise and payment of the Aggregate Exercise Price, the Company
shall issue and cause to be delivered to the Holder a certificate or certificates (in the name of the Holder) for the Exercise Amount. 

SECTION 2. 
 PAYMENT OF
TAXES 
 The Holder shall pay all taxes attributable to the initial issuance of shares of Common Stock or other securities issuable upon the exercise of
this Warrant or issuable pursuant to Section 5 hereof. 
 SECTION 3. 

REPLACEMENT WARRANT 
 IN CASE THIS WARRANT
IS MUTILATED, LOST, STOLEN OR DESTROYED, THE COMPANY SHALL ISSUE AND DELIVER IN EXCHANGE AND SUBSTITUTION FOR AND UPON CANCELLATION OF THE MUTILATED WARRANT, OR IN LIEU OF AND IN SUBSTITUTION FOR THE WARRANT LOST, STOLEN OR DESTROYED, A NEW WARRANT
OF LIKE TENOR AND REPRESENTING AN EQUIVALENT RIGHT OR INTEREST, BUT ONLY UPON RECEIPT OF REASONABLE EVIDENCE OF SUCH LOSS, THEFT OR DESTRUCTION OF SUCH WARRANT. 

SECTION 4. 
 COVENANTS

 (a) Validly Issued Shares. The Company covenants that all shares of Common Stock that may be issued pursuant to this Warrant,
assuming full payment of the Aggregate Exercise Price, shall, upon delivery by the Company, be duly authorized and validly issued, fully paid and nonassessable, free from all liens and charges with respect to the issue or delivery thereof and
otherwise free of all other security interests and encumbrances (other than restrictions under the Stockholders Agreements and applicable federal and/or state securities laws). 

(b) Reservation of Shares. The Company shall at all times reserve and keep available out of the aggregate of its authorized but
unissued shares of Common Stock such number of its duly authorized shares of Common Stock as shall be sufficient to enable the Company to issue Common Stock to the Holder or its permitted designee upon exercise of this Warrant. 

  
 -2- 

 SECTION 5. 

ADJUSTMENT TO EXERCISE PRICE; OTHER ADJUSTMENTS 

Under certain conditions, the Exercise Price is subject to adjustment as set forth in this Section 5. 

(a) Adjustments to Number of Shares. Upon any adjustment of the Exercise Price as provided in Section 5(b),
the Holder shall thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Common Stock obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number
of shares of Common Stock purchasable hereunder immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. 

(b) Adjustments to Exercise Price. The Exercise Price shall be subject to adjustment from time to time as follows and, thereafter, as
adjusted, shall be deemed to be the Exercise Price hereunder. In case at any time or from time to time the Company shall: 
 (i) issue to the
holders of any of its Common Stock a dividend payable in, or other distribution of, shares of Common Stock (a “Stock Dividend”); 

(ii) subdivide any of its classes of its outstanding shares of Common Stock into a larger number of shares of Common Stock, including without
limitation by means of a stock split (a “Stock Subdivision”); or 
 (iii) combine any of its classes of its outstanding
shares of Common Stock into a smaller number of shares of Common Stock (a “Stock Combination”), 
 then the Exercise Price in effect
immediately prior thereto shall be (1) proportionately increased in the case of a Stock Combination, and (2) proportionately decreased in the case of a Stock Dividend and Stock Subdivision. In the event the Company shall declare, pay or
make any dividend on the shares of any of its Common Stock payable in any right to acquire shares of Common Stock for no consideration, then the Company shall be deemed to have made a Stock Dividend in an amount of shares equal to the maximum number
of shares issuable upon exercise of such rights to acquire shares of Common Stock. 
 (c) Changes in Common Stock. In case at any
time the Company shall initiate any transaction or be a party to any transaction (including, without limitation, a merger, consolidation, share exchange, sale, lease or other disposition of all or substantially all of the Company’s assets,
liquidation, recapitalization or reclassification of the Common Stock) in connection with which the previous Outstanding Common Stock shall be changed into or exchanged for different securities of the Company or Capital Stock or other securities of
another corporation or interests in a non-corporate entity or other property (including cash) or any combination of the foregoing (each such transaction being herein called a “Transaction”),
then the Company shall use reasonable best efforts to include, as a condition of the consummation of the Transaction, that lawful, enforceable and adequate provision be made to entitle the Holder to a new warrant in form and substance similar to,
and in exchange for, this Warrant to purchase all or a portion of such securities or other property; provided that, if the Company is unable to secure such new warrant and the then-current fair market value of one share of Common Stock is greater
than the Exercise Price, then the Holder will exercise this Warrant in connection with the consummation of the Transaction for, in lieu of the Warrant Shares issuable upon such exercise, the securities or other property (including cash) to which
such Holder would have been entitled upon consummation of the Transaction if such Holder had exercised this Warrant immediately prior thereto (subject to adjustments from and after the consummation date as nearly equivalent as possible to the
adjustments provided for in this Section 5). The foregoing provisions of this Section 5(c) shall similarly apply to successive Transactions. 

  
 -3- 

 (d) Other Action Affecting Common Stock. In case at any time or from time to time the
Company shall take any action of the type contemplated in Section 5(b) hereof but not expressly provided for by such provisions, the Exercise Price shall be adjusted in such manner as to satisfy the provisions of this
Section 5. 
 (e) Notices. Whenever the Exercise Price is to be adjusted pursuant to this
Section 5, unless otherwise agreed by the Holder, the Company shall promptly (and in any event within 20 days after the event requiring the adjustment) notify the Holder of the event requiring the adjustment and the
method by which such adjustment is to be calculated. 
 SECTION 6. 

REPRESENTATIONS AND WARRANTIES 

Company represents and warrants to Holder as follows: 

(a) No Impairment. The Company will not, by amendment of its Certificate of Incorporation or through any reorganization,
recapitalization, transfer of assets, consolidation, merger, share exchange, dissolution or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant and will at all times in good faith
assist in the carrying out of all such terms. Company shall provide prompt notice to Holder of any amendments to or other changes affecting its Certificate of Incorporation, Bylaws, Stockholders Agreement or other documents (including any newly
adopted documents) which could affect the rights and obligations of either Party under this Warrant. 
 (b) Organization and
Authority. Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and has all necessary power and authority to enter into this Warrant and any ancillary agreements, to carry out
its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. Company is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by
it or the operation of its business makes such licensing or qualification necessary. The execution and delivery of this Warrant and the ancillary agreements by Company, the performance by Company of its respective obligations hereunder and
thereunder and the consummation by Company of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of Company. Upon execution this Warrant will constitute legal, valid and binding obligations
of Company, enforceable against Company, in accordance with its respective terms except to the extent that the enforcement thereof may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter
in effect relating to creditors’ rights generally, and (ii) general principles of equity regardless of whether enforceability is considered in a proceeding in equity or at law. 

(c) No Conflict. The execution, delivery and performance of this Warrant and any ancillary agreements by Company do not and will not
(a) violate, conflict with or result in the breach of any provision of its Certificate of Incorporation, Bylaws or the Stockholders Agreement, (b) conflict with or violate (or cause an event which could materially and adversely affect the
transactions contemplated by this Warrant as a result of) any law, governmental regulation or governmental order applicable to them or any of their respective assets, properties or businesses, or (c) conflict with, result in any breach of,
constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or
cancellation of, or result in the creation of any lien on any of the assets or properties of any of them pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or other instrument or
arrangement to which Company is a party or by which any of its respective assets or properties is bound or affected. 

  
 -4- 

 (d) No Litigation or Adverse Events. There are no outstanding orders, judgments,
injunctions, awards or decrees of any court, arbitrator or governmental or regulatory body involving Company. No suit, action or legal, administrative, arbitration or other proceeding or reasonable basis therefor, or no investigation by any
governmental agency, pertaining to Company or its assets is pending or has been threatened against Company which could adversely affect the financial condition or prospects of Company or the conduct of the business thereof or any of its assets or
materially adversely affect the ability of Company to consummate the transactions contemplated by this Warrant. There is no dispute of any kind with any person under any contract or agreement which materially adversely affects, or may materially
adversely affect, Corporation, its business or operation of its assets. 
 (e) Brokers. No broker, finder or investment banker is
entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Warrant or any ancillary agreements based upon arrangements made by or on behalf of Company. 

SECTION 7. 
 TRANSFERS OF
THE WARRANT AGREEMENT OR WARRANT SHARES 
 (a) Restrictions on Transfers. The Holder may not (i) Transfer this Warrant other
than to a Controlled Affiliate of Holder, or (ii) Transfer any Warrant Shares, without the prior written consent the Board of Directors of the Company or as otherwise permitted under the Stockholders Agreements. 

(b) Non-Circumvention. The Holder agrees that it will not take any action with respect to the
sale or issuance of equity interests in the Holder or any Affiliate of Holder where the purpose or effect of such action is to avoid the Transfer restrictions of this Section 7. 

(c) Acknowledgment of the Holder. This Warrant has not been, and the Warrant Shares at the time of their issuance may not be,
registered under the Securities Act and except as provided in this Warrant, the Company shall not be required to so register this Warrant and the Warrant Shares. This Warrant and the Warrant Shares are issued or issuable subject to the provisions
and conditions contained herein, and every Holder hereof by accepting the same (i) agrees with the Company to such provisions and conditions, and (ii) represents to the Company that this Warrant has been acquired and the Warrant Shares
will be acquired for the account of the Holder for investment and not with a view to or for sale in connection with any distribution thereof. 

(d) Compliance with Securities Laws. The Holder agrees that this Warrant and the Warrant Shares may not be sold or otherwise disposed
of except pursuant to an effective registration statement under the Securities Act and applicable state securities laws or pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities
laws. In the event that the Holder transfers this Warrant or the Warrant Shares pursuant to an applicable exemption from registration, the Company may request, at its expense, that the Holder deliver an opinion of counsel reasonably acceptable to
the Company that the proposed transfer does not violate the Securities Act and applicable state securities laws. Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on
the date of the final prospectus relating to the Company’s initial public offering (the “IPO”) and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty
(180) days), or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and
opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to
purchase, 

  
 -5- 

 
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Capital Stock held immediately
prior to the effectiveness of the registration statement for the IPO; or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Capital Stock, whether
any such transaction described in clause (a) or (b) above is to be settled by delivery of Capital Stock or other securities, in cash or otherwise. The underwriters in connection with the IPO are intended third-party beneficiaries of this
subsection and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the IPO that are
consistent with this subsection or that are necessary to give further effect thereto. 
 (e) Restrictive Securities Legend. The
certificate representing the Warrant Shares shall bear the restrictive legends as follows: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED
UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH
OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER,
PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT, AS THE SAME MAY BE AMENDED FROM
TIME TO TIME, BY AND AMONG THE STOCKHOLDER, THE CORPORATION AND CERTAIN OTHER HOLDERS OF STOCK OF THE CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION. 

THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY OF WHICH MAY BE OBTAINED UPON
WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT VOTING AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON
TRANSFER AND OWNERSHIP SET FORTH THEREIN. 
 SECTION 8. 

DEFINITIONS 
 As used
herein, the following terms shall have the following meanings. 
 An “Affiliate” of a specified Person shall mean a Person
which, directly or indirectly, through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, the Person specified. 

  
 -6- 

 “Agreement” has the meaning set forth in the Preamble. 

“Aggregate Exercise Price” has the meaning set forth in Section 1(a). 

“Capital Stock” means, with respect to any Person, all of the shares of capital stock, including, but not limited to, common
and preferred shares, of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in)
such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares
(or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other
interests are outstanding on any date of determination. 
 “Certificate of Incorporation” means the Certificate of
Incorporation of the Company, as in effect on the date hereof, as amended from time to time. 
 “Company” has the meaning
set forth in the Preamble. 
 “Control” means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise. 

“Convertible Securities” means evidences of indebtedness, shares of stock or other securities (including, but not limited to
options and warrants) which are by their terms directly or indirectly convertible, exercisable or exchangeable, with or without payment of additional consideration in cash or property, for shares of Common Stock, either immediately or upon the onset
of a specified date or the happening of a specified event. 
 “Exercise Amount” has the meaning set forth in
Section 1(a).  
 “Exercise Price” has the meaning set forth in the Preamble. 

“Holder” has the meaning set forth in the Preamble. 

“Initial Term” has the meaning set forth in the Agreement. 

“New Users” has the meaning set forth in the Agreement. 

“Notice of Exercise” has the meaning set forth in Section 1(a).  

“Option Period” has the meaning set forth in Section 1(a). 

“Outstanding Common Stock” of the Company means, as of the date of determination, the sum (without duplication) of the
following: (a) the number of shares of Common Stock then outstanding at the date of determination; (b) the number of shares of Common Stock then issuable upon the exercise of this Warrant (as such number of shares may be adjusted pursuant
to the terms hereof); and (c) the number of shares of Common Stock then issuable upon the exercise or conversion of Convertible Securities and any warrants, options or other rights to subscribe for or purchase Common Stock or Convertible
Securities (including any unvested options and securities even though not then exercisable for or convertible into Common Stock). 

  
 -7- 

 “Person” means any individual, corporation, proprietorship, firm,
partnership, limited partnership, limited liability company, trust, association or other entity. 
 “Securities Act” means
the Securities Act of 1933, as amended. 
 “Stock Combination” has the meaning set forth in
Section 5(b)(iii). 
 “Stock Dividend” has the meaning set forth in
Section 5(b)(i). 
 “Stockholders Agreements” means (a) the Right of First Refusal and Co-Sale Agreement dated as of April 22, 2014, by and among the Company and certain stockholders, as may be amended, restated or otherwise modified from time to time, and (b) the Voting Agreement dated as
of April 22, 2014, by and among the Company and certain stockholders, as may be amended, restated or otherwise modified from time to time. 

“Stock Subdivision” has the meaning set forth in Section 5(b)(ii). 

“Transaction” has the meaning set forth in Section 5(c). 

“Transfer” means any direct or indirect transfer, donation, sale, assignment, pledge, encumbrance, hypothecation, gift,
creation of a security interest in or lien on, or other disposition, irrespective of whether any of the foregoing are effected with or without consideration, voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise,
inter vivos or upon death. 
 “Warrant” has the meaning set forth in the Preamble. 

“Warrant Shares” means (a) the shares of Common Stock issued or issuable upon exercise of this Warrant in accordance
with its terms, and (b) all other shares of the Company’s Capital Stock issued with respect to such shares by way of stock dividend, stock split or other reclassification or in connection with any merger, consolidation, recapitalization or
other reorganization affecting the Company’s Capital Stock. 
 SECTION 9. 

SURVIVAL OF PROVISIONS 
 ALL OF THE
PROVISIONS OF THIS WARRANT SHALL EXPRESSLY SURVIVE ANY EXERCISE OF THIS WARRANT UNTIL THE DATE ON WHICH THE HOLDER NO LONGER HOLDS ANY WARRANT SHARES. 

SECTION 10. 
 DELAYS,
OMISSIONS AND INDULGENCES 
 It is agreed that no delay or omission to exercise any right, power or remedy accruing to the Holder upon
any breach or default of the Company under this Warrant shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein, or of or in any similar breach or default
thereafter occurring; nor shall any waiver of any single breach or default be 

  
 -8- 

 
deemed a waiver of any other breach or default theretofore or thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on the Holder’s
part of any breach or default under this Warrant, or any waiver on the Holder’s part of any provisions or conditions of this Warrant must be in writing and that all remedies, either under this Warrant, or by law or otherwise afforded to the
Holder, shall be cumulative and not alternative. 
 SECTION 11. 

CAPTIONS 
 The titles and
captions of the Sections and other provisions of this Warrant are for convenience of reference only and are not to be considered in construing this Warrant. 

SECTION 12. 
 NOTICES

 All notices, demands and other communications provided for or permitted hereunder shall be made in writing and shall be by registered
or certified first-class mail, return receipt requested, telecopy, overnight courier service or personal delivery: 
  

	 	(i)	 If to the Holder, addressed as follows: 

Cerner Corporation 
 2800
Rockcreek Parkway 
 North Kansas City, Missouri 64117 

Attention: Chief Financial Officer 

with a copy to: 
 Cerner
Corporation 
 Chief Legal Officer 

2800 Rockcreek Parkway 
 North
Kansas City, MO 64117 
  

	 	(ii)	 If to the Company, addressed as follows: 

Livongo Health, Inc. 
 444 N
Michigan Ave 
 Suite 2880 

Chicago, IL 60611 
 with a copy
to: 
 Vedder Price P.C. 
 222
N. LaSalle Street, Suite 2400 
 Chicago, Illinois 60601 

  
 -9- 

 All such notices and communications shall be deemed to have been duly given: when delivered
by hand, if personally delivered; when delivered by courier, if delivered by commercial overnight courier service; five (5) business days after being deposited in the mail, postage prepaid, if mailed; and when receipt is acknowledged, if
telecopied. 
 SECTION 13. 

SUCCESSORS AND ASSIGNS 

This Warrant shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 

SECTION 14. 
 AMENDMENTS

 Neither this Warrant nor any term hereof may be amended, changed, waived or terminated without the prior written consent of the
Holder and the Company to such action. 
 SECTION 15. 

SEVERABILITY 
 If any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other
respect and of the remaining provisions hereof shall not be in any way impaired, unless the provisions held invalid, illegal or unenforceable shall substantially impair the benefits of the remaining provisions hereof. 

SECTION 16. 
 GOVERNING
LAW 
 This Warrant is to be construed and enforced in accordance with and governed by the laws of the State of Delaware and without
regard to the principles of conflicts of law of such state. 
 SECTION 17. 

ENTIRE AGREEMENT 
 This
Warrant is intended by the parties as a final expression of their agreement and is intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein and
therein. 
 SECTION 18. 

NO RIGHTS AS AN EQUITY HOLDER 

Nothing contained herein shall entitle the Holder to any rights as an equity holder or member of the Company or to be deemed the holder of any
securities that may at any time be issuable on the exercise of the rights hereunder for any purpose nor shall anything contained herein be construed to confer upon the Holder, as such, until the rights under this Warrant shall have been first
exercised and the Warrant Shares purchasable upon exercise of the rights hereunder shall have become deliverable as provided herein. 

  
 -10- 

 SECTION 19. 

RULES OF CONSTRUCTION 

Unless the context otherwise requires, “or” is not exclusive, and references to sections or subsections refer to sections or
subsections of this Warrant. All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as the context may require. 

SECTION 20. 
 FEES AND
EXPENSES 
 All fees and expenses (including, without limitation, legal, auditing and accounting fees, costs and expenses) incurred in
connection with considering, pursuing, negotiating, documenting or consummating this Warrant and the transactions contemplated hereby shall be borne and paid solely by the party incurring such fees, costs and expenses. 

[Remainder of Page Intentionally Omitted] 

  
 -11- 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be issued and executed in
its corporate name by its duly authorized officer as of the date of issuance set forth above. 
  

			
	 LIVONGO HEALTH, INC.

a Delaware corporation

		
	By: 	 	/s/ Brian Vendenberg
	Name: Brian Vandenberg
	Title: General Counsel

 ACKNOWLEDGED AND ACCEPTED this 1st day of March, 2015. 

 

			
	 CERNER CAPITAL, INC. 
 a
Delaware corporation

		
	By: 	 	/s/ Marc E. Elkins
	Name: Marc E. Elkins
	Title: Assistant Secretary

 EXHIBIT A 

NUMBER OF SHARES FOR WHICH 

THE WARRANT SHALL BE EXERCISABLE 

The Warrant Shares shall vest and become exercisable during the Option Period as follows: 

1. 1,389,447 Warrant Shares shall vest and become exercisable at the end of the first year of the Initial Term if the Agreement is then in effect. This Warrant
shall terminate and be of no further force or effect if the Agreement is not in effect at the end of the first year of the Initial Term. 
 2. Additional
Warrant Shares as indicated below shall vest and become exercisable as of the end of the Initial Term if Cerner has enrolled the following number of cumulative New Users as of the end of the Initial Term: 

(a) 694,724 Warrant Shares if Cerner has enrolled at least 75,000 but less than 100,000 cumulative New Users; 

(b) 1,389,447 Warrant Shares if Cerner has enrolled at least 100,000 but less than 125,000 cumulative New Users; or 

(c) 2,084,171 Warrant Shares if Cerner has enrolled at least 125,000 cumulative New Users. 

 EXHIBIT B 

NOTICE OF EXERCISE 
  

			
	To:	  	                                      
  
		  	                                      
  
		  	                                      
  
		  	                                      
  
		  	                                      
  

 1. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Warrant.
The undersigned, pursuant to the provisions of the Warrant, hereby elects to exercise the Warrant with respect to shares of Common Stock issuable pursuant to the Warrant. Subject to adjustment after confirmation with the Company, the Holder has
calculated the number of Warrant Shares to be              shares of Common Stock. 

2. Subject to adjustment after confirmation with the Company, the undersigned herewith tenders payment for such shares, together with any
applicable transfer taxes, in the following amount $[                    ] payable in full in the form of wire transfer or a certified or
official bank check in same-day funds. 
 3. Please issue a certificate or certificates representing
the shares issuable in respect hereof under the terms of the attached Warrant, as follows: 
  

			
		  	  
 (Name of Record
Holder)

 and deliver such certificate or certificates to the following address: 

 

			
		  	  
 (Address of Record
Holder/Transferee)

 4. The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned
for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares. 

 

									
		 		 		 		 	  
 (Signature)

					
		 		 		 		 	
		 	  
 (Date)EX-4.4

 Exhibit 4.4 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE
STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO
RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT TO PURCHASE STOCK

  

			
	Company:	 	LIVONGO HEALTH, INC., a Delaware corporation
	Number of Shares:	 	See Paragraph A below
	Class of Stock:	 	Common Stock
	Warrant Price:	 	$0.40 per share
	Issue Date:	 	April 16, 2015
	Expiration Date:	 	April 16, 2025 (Subject to Section 4.1)

 THIS WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable consideration,
the receipt of which is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the
“Shares”) of LIVONGO HEALTH, INC., a Delaware corporation (the “Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and
conditions set forth in this Warrant. 
 A. The number of fully paid and non-assessable shares for
which this Warrant shall be exercisable shall equal the sum of (i) one percent (1.0%) of each Term Loan divided by (ii) the Warrant Price. For the sake of clarity, the Number of Shares shall be earned with each Term Loan as stated in the
previous sentence, but shall not exceed the quotient that is one percent (1.0%) of the Term Loan Amount divided by the Warrant Price. 

ARTICLE 1 
 EXERCISE

 1.1 Method of Exercise. Holder may exercise this Warrant from time to time for all or any part of the unexercised Shares by
delivering a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company (or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the
Company a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. Notwithstanding any other provision

  
 1 

 
hereof, if an exercise of any portion of this Warrant is to be made in connection with a public offering or an Acquisition (as defined below), such exercise may at the election of the Holder be
conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the closing of such transaction. 

1.2 [Intentionally Omitted.] 

1.3 Delivery of Certificate and New Warrant. Within thirty (30) days after Holder exercises this Warrant and the Company receives
payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired. 

1.4 Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, upon delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

 1.5 Acquisition of the Company. 

1.5.1 “Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any sale,
license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the voting securities of the Company or other transaction or
series of related transactions where the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than fifty percent (50%) of the outstanding voting securities of the surviving entity
after the transaction or series of related transactions. 
 1.5.2 Treatment of Warrant in the Event of an Acquisition.
The Company shall give Holder written notice at least twenty (20) days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company, (ii) successor or
surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition. 

(a) If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as
would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and
the Warrant Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions hereof. 

  
 2 

 (b) If the Acquirer refuses to assume this Warrant in connection with the
Acquisition, the Company shall give Holder an additional written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other provision of this Warrant to the contrary, Holder may
immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior
to the closing of the Acquisition. Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as
defined below), then effective as of the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the option to elect to put this Warrant to the Company for a per Share amount equal to the difference between
the Acquisition consideration payable for one Share and the Warrant Price. As used herein, an “Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the
Shares consists entirely of cash and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior
to the closing of such Acquisition may be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement
under the Act. 
 ARTICLE 2 

ADJUSTMENTS TO THE SHARES 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or other
securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which
Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 
 2.2
Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder
shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification,
exchange, substitution, or other event. Such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the
Company’s Certificate of Incorporation upon the closing of a registered public offering of the Company’s common stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The
new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price, the number of securities or
property issuable upon exercise of the new warrant and expiration date. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

  
 3 

 2.3 Adjustments for Combinations. Etc. If the outstanding Shares are combined or
consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are split or multiplied, by reclassification or otherwise, into a greater
Number of Shares, the Warrant Price shall be proportionately decreased. 
 2.4 No Impairment. The Company shall not, by amendment of
its Certificate of Incorporation or Bylaws or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any
of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect
Holder’s rights under this Article 2 against dilution or other impairment. 
 2.5 Certificate as to Adjustments. Upon each
adjustment of the Warrant Price or number of Shares, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth such adjustment and the facts upon
which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price and number of Shares in effect upon the date thereof and the series of adjustments leading to such Warrant Price
and number of Shares. 
 2.6 Limitations on Liability. Nothing contained in this Warrant shall be construed as imposing any
liabilities on Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. 

2.7 Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be issued shall
be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount in cash computed by multiplying the fractional
interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share. 
 ARTICLE 3 

REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1 Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows: 

3.1.1 The initial Warrant Price referenced on the first page of this Warrant is not greater than the fair market value of the
Shares as of the date of this Warrant. 

  
 4 

 3.1.2 This Warrant is and any Warrant issued in substitution for or
replacement of this Warrant shall be, upon issuance, duly authorized and validly issued. All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the
Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

 3.1.3 The Company’s capitalization table delivered to Holder as of the Issue Date is true and complete as of the
Issue Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution
upon its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any
class or series or other rights; (c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets,
or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least ten (10) days prior written notice of the date on which a record will be taken for such dividend, distribution, or
subscription rights (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and (2) in the case of the matters
referred to in (c) and (d) above at least ten (10) days prior written notice of the date when the same will take place (and specifying the date on which the holders of stock will be entitled to exchange their stock for securities or other
property deliverable upon the occurrence of such event). Upon request, the Company shall provide Holder with such information reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares in the case of matters
referred to (a), (b), (c) and (d) herein above. 
 3.3 Information Rights. So long as the Holder holds this Warrant and/or any
of the Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communications, information and/or communiques to the shareholders of the Company, (b) within one hundred fifty (150) days after the end
of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty five (45) days after the end of each calendar month through
February 2015, and within thirty (30) days after the end of each calendar month thereafter, the Company’s monthly, unaudited financial statements. In addition, and without limiting the generality of the foregoing, so long as the Holder
holds this Warrant and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its business and financial condition as would be afforded to a holder of the class of Shares under
applicable state law and/or any agreement with any holder of the class of Shares. 

  
 5 

 3.4 Registration Under the Securities Act. 

(a) If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the
Holder) any of its Common Stock under the Securities Act of 1933 in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give Holder notice of such
registration. Upon the request of Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 3.3(b), cause to be registered all of the Shares that Holder has
requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 3.3 before the effective date of such registration, whether or not Holder has elected
to include Shares in such registration. “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan;
(ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the
Shares; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 3.3(a),
the Company shall not be required to include any of the Holder’s Shares in such underwriting unless Holder accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the
underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. 
 (c) All expenses (other
than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 3.3, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of
counsel for the Company shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration if the registration request is subsequently withdrawn at the request of Holder.
“Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Shares, and fees and disbursements of counsel for any Holder. 

  
 6 

 ARTICLE 4 

MISCELLANEOUS 
 4.1
Term: Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above; provided, however, that if the Company completes its initial·
public offering within the three-year period immediately prior to the Expiration Date, the Expiration Date shall automatically be extended until the third anniversary of the effective date of the Company’s initial public offering. The Company
shall give Holder written notice of Holder’s right to exercise this Warrant not less than ninety (90) days before the Expiration Date. If the notice is not so given, the Expiration Date shall automatically be extended until ninety
(90) days after the date the Company delivers such notice to Holder. The Company agrees that Holder may terminate this Warrant, upon notice to the Company, at any time in its sole discretion. 

4.2 Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any)
shall be imprinted with a legend in substantially the following form: 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

4.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company
shall not require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated
(“Comerica”), or any other affiliate of Bank (“Bank Affiliate”). 
 4.4 Transfer Procedure. After receipt of the
executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of
Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) to an affiliate of Holder by giving
the Company notice of the portion of this Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if
applicable) and such affiliate shall then be entitled to all the rights of Holder under this Warrant and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the
name of the affiliate that exercises this Warrant. The terms and conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns. Each such
notice of transfer shall describe the manner and 

  
 7 

 
circumstances of the proposed transfer in sufficient detail and, other than a transfer to Ventures or other affiliate of Holder, if reasonably requested by the Company, shall be accompanied at
such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be
effected without registration under the Securities Act of 1933; (ii) a “no action” letter from the Securities Exchange Commission (the “SEC”) to the effect that the proposed transfer without registration will not result in a
recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed transfer may be effected without registration under
the Securities Act of 1933, whereupon the Holder shall be entitled to transfer this Warrant or the Shares issuable upon exercise of this Warrant in accordance with the terms of the notice given by the Holder to the Company. Each certificate,
instrument or book entry evidencing this Warrant or the Shares issuable upon exercise of this Warrant transferred as above provided shall bear the appropriate restrictive legend. 

4.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and
effective when: (i) given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally recognized overnight courier service (such as, but not limited to, Federal Express, DHL or UPS), fee prepaid,
or (ii) on the date sent by email or facsimile if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient. Such communications must be sent to the respective parties
at the address or facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon the receipt of executed Warrant and initial transfer described
in Article 5.4 above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

Comerica Ventures Incorporated 

Attn: Warrant Administrator 

1717 Main Street, 5th Floor, MC 

6406 Dallas, Texas 75201 
 All
notices to the Company shall be addressed as follows: 
 LIVONGO HEALTH, INC. 

444 N. Michigan Ave., Suite 2880 

Chicago, IL 60611 
 4.6
Amendments; Waiver. This Warrant and any term hereof may be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective
unless explicitly set forth in writing and signed by the party so waiving. No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Warrant shall operate or be construed as a waiver thereof, nor shall
any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

  
 8 

 4.7 Cumulative Remedies. The rights and remedies provided in this Warrant are
cumulative and are not exclusive of, and are in addition and not in substitution for, any other rights or remedies available at law, in equity or otherwise. 

4.8 No Strict Construction. This Warrant shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting an instrument or causing any instrument to be drafted. 
 4.9 Governing Law. This Warrant
shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 

[Remainder of page left intentionally blank] 

  
 9 

			
	LIVONGO HEALTH, INC.

 
			
		
	By: 	 	 /s/ Mario A. Christopher Na

			
	Name:	 	Mario A. Christopher
	Title:	 	CFO

 [SIGNATURE PAGE TO WARRANT TO PURCHASE STOCK] 

 APPENDIX I 

NOTICE OF EXERCISE 
 1. The
undersigned hereby elects to purchase shares of the stock of LIVONGO HEALTH, INC. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full. 

2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified
below: 
 Comerica Ventures Incorporated 

Attn: Warrant Administrator 
 1717
Main Street, 5th Floor, MC 
 6406 Dallas, Texas 75201 

3. The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a
view toward the resale or distribution thereof except in compliance with applicable securities laws. 
 COMERICA VENTURES INCORPORATED or 

Assignee 
  

                          
                                         
      
 (Signature) 
  

                          
                                         
      
 (Name and Title) 
  

                          
                                         
      
 (Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]